ATE458754T1 - Screening-verfahren, verfahren zur aufreinigung nichtdiffundierbarer a-beta-oligomere, selektive antikörper gegen diese nichtdiffundierbaren a- beta-oligomere und verfahren zur herstellung dieser antikörper - Google Patents

Screening-verfahren, verfahren zur aufreinigung nichtdiffundierbarer a-beta-oligomere, selektive antikörper gegen diese nichtdiffundierbaren a- beta-oligomere und verfahren zur herstellung dieser antikörper

Info

Publication number
ATE458754T1
ATE458754T1 AT06707413T AT06707413T ATE458754T1 AT E458754 T1 ATE458754 T1 AT E458754T1 AT 06707413 T AT06707413 T AT 06707413T AT 06707413 T AT06707413 T AT 06707413T AT E458754 T1 ATE458754 T1 AT E458754T1
Authority
AT
Austria
Prior art keywords
diffusable
antibodies
beta oligomers
globulomers
derivatives
Prior art date
Application number
AT06707413T
Other languages
English (en)
Inventor
Heinz Hillen
Andreas Striebinger
Patrick Keller
Stefan Barghorn
Ulrich Ebert
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36581967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE458754(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Application granted granted Critical
Publication of ATE458754T1 publication Critical patent/ATE458754T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
AT06707413T 2005-03-05 2006-03-03 Screening-verfahren, verfahren zur aufreinigung nichtdiffundierbarer a-beta-oligomere, selektive antikörper gegen diese nichtdiffundierbaren a- beta-oligomere und verfahren zur herstellung dieser antikörper ATE458754T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05004858 2005-03-05
US66447705P 2005-03-23 2005-03-23
EP05006568 2005-03-24
US74086605P 2005-11-30 2005-11-30
PCT/EP2006/001984 WO2006094724A2 (en) 2005-03-05 2006-03-03 Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies

Publications (1)

Publication Number Publication Date
ATE458754T1 true ATE458754T1 (de) 2010-03-15

Family

ID=36581967

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06707413T ATE458754T1 (de) 2005-03-05 2006-03-03 Screening-verfahren, verfahren zur aufreinigung nichtdiffundierbarer a-beta-oligomere, selektive antikörper gegen diese nichtdiffundierbaren a- beta-oligomere und verfahren zur herstellung dieser antikörper

Country Status (14)

Country Link
US (1) US20090035295A1 (de)
EP (2) EP1861422B1 (de)
KR (1) KR20080021585A (de)
CN (1) CN101365717A (de)
AT (1) ATE458754T1 (de)
AU (1) AU2006222193B2 (de)
BR (1) BRPI0608076A2 (de)
CA (1) CA2599792A1 (de)
DE (1) DE602006012459D1 (de)
ES (1) ES2340414T3 (de)
IL (1) IL185392A0 (de)
MX (1) MX2007010687A (de)
WO (1) WO2006094724A2 (de)
ZA (1) ZA200707234B (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
US8906864B2 (en) 2005-09-30 2014-12-09 AbbVie Deutschland GmbH & Co. KG Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
PT1954718E (pt) * 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
KR20180058863A (ko) 2005-11-30 2018-06-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
AU2013200177B2 (en) * 2005-11-30 2014-10-02 Abbvie Deutschland Gmbh & Co Kg Monoclonal antibodies against amyloid beta protein and uses thereof
CA2632822C (en) 2005-12-12 2018-08-28 Ruth Greferath A beta 1-42 specific monoclonal antibodies with therapeutic properties
PL2004688T5 (pl) 2006-03-23 2014-09-30 Bioarctic Neuroscience Ab Ulepszone przeciwciała wobec protofibryli oraz ich zastosowania
PL2468770T3 (pl) 2006-07-14 2018-07-31 Ac Immune S.A. Humanizowane przeciwciało przeciw amyloidowi beta
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
EP2099826B1 (de) * 2007-01-05 2013-10-16 University Of Zurich Anti-beta-amyloid-antikörper und verwendung davon
DK2104682T3 (en) 2007-01-11 2017-01-16 Michael Bacher DIAGNOSIS AND TREATMENT OF ALZHEIMER'S AND OTHER DEMENTIA DISEASES
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
NZ599497A (en) * 2007-06-12 2013-11-29 Ac Immune Sa Humanized antibodies to amyloid beta
EP2586795B1 (de) 2007-10-05 2018-05-16 Genentech, Inc. Verwendung eines Anti-Amyloid-Beta-Antikörpers bei Augenkrankheiten
EP2650308A3 (de) * 2007-10-05 2014-11-12 Genentech, Inc. Verwendung eines Anti-Amyloid-Beta-Antikörpers bei Augenerkrankungen
EP2210901A4 (de) * 2007-10-19 2012-04-25 Immunas Pharma Inc Zur spezifischen bindung an ein oligomer fähiger antikörper, und dessen verwendung
EP3121277B1 (de) 2008-02-08 2018-04-11 Immunas Pharma, Inc. Zur spezifischen bindung an ab-oligomer fähiger antikörper und verwendung davon
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
US20100173828A1 (en) * 2008-07-25 2010-07-08 Abbott Gmbh & Co. Kg Aß(X - 38 .. 43) oligomers, and processes, compositions, and uses thereof
CN102203124A (zh) * 2008-07-25 2011-09-28 雅培制药有限公司 淀粉状蛋白β肽类似物，其寡聚物，用于制备的方法以及包括所述类似物或寡聚物的组合物，及其用途
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
EP3521309A1 (de) 2008-12-19 2019-08-07 Biogen International Neuroscience GmbH Menschliche anti-alpha-synuclein-antikörper
CN105968022A (zh) 2009-04-09 2016-09-28 考格尼申治疗股份有限公司 认知衰退的抑制剂
WO2010119704A1 (en) 2009-04-17 2010-10-21 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
US8512677B2 (en) 2009-04-27 2013-08-20 Case Western Reserve University Pyro-glutamate Aβ targeting agents
BR112012002246A2 (pt) 2009-07-31 2019-09-24 Cognition Therapeutics Inc composto, composto ou sal farmaceutico aceitavel deste, composição farmaceutica, metodo para inibir, tratar e/ou reduzir o declinio cognitivol e/ou doença de akzhmer em um paciente
ES2624835T3 (es) 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
US8613924B2 (en) 2009-08-06 2013-12-24 Immunas Pharma, Inc. Antibodies that specifically bind to A beta oligomers and use thereof
MX2012006560A (es) 2009-12-08 2012-10-05 Abbott Gmbh & Co Kg Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
US20130071330A1 (en) * 2010-02-26 2013-03-21 Susan Catalano Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
MY164579A (en) 2010-07-30 2018-01-15 Ac Immune Sa Safe and functional humanized antibodies
EP3533803B1 (de) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antikörper
WO2012054333A2 (en) * 2010-10-20 2012-04-26 Merck Sharp & Dohme Corp. Methods for identifying inhibitors of abeta42 oligomers
SG192596A1 (en) 2011-02-02 2013-09-30 Cognition Therapeutics Inc Isolated compounds from turmeric oil and methods of use
US9061006B2 (en) 2011-03-08 2015-06-23 Ramot At Tel-Aviv University Ltd. Compositions and methods for diagnosing and treating phenylketonuria (PKU)
MX357193B (es) 2011-06-23 2018-06-29 Univ Zuerich Moleculas de union anti-alfa sinucleina.
PE20190907A1 (es) 2012-01-27 2019-06-26 AbbVie Deutschland GmbH and Co KG Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
CN104662423A (zh) * 2012-03-13 2015-05-27 杨森阿尔茨海默氏症免疫治疗公司 阿兹海默氏病的诊断、预后和监测中的寡聚体Aβ
DK3099296T3 (en) 2014-01-31 2019-04-15 Cognition Therapeutics Inc ISO-INDOLINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE
SMT202100263T1 (it) 2014-07-10 2021-07-12 Eisai R&D Man Co Ltd Anticorpi leganti protofibrille a-beta migliorati
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
KR101856838B1 (ko) * 2016-02-17 2018-06-19 이희정 베타-아밀로이드 올리고머에 대한 압타머 및 이의 용도
CN106519029B (zh) * 2016-10-31 2020-03-17 山东泰邦生物制品有限公司 一种Aβ寡聚体抗体的制备工艺
IL270251B2 (en) 2017-05-15 2025-01-01 Cognition Therapeutics Inc 1-Phenyl-1,1-dimethyl-2-(piperidinyl/pyrrolidinyl/piperazinyl)ethane derivatives and pharmaceutical preparations containing them
EP4233901A3 (de) 2017-08-22 2023-09-06 Biogen MA Inc. Pharmazeutische zusammensetzungen mit anti-beta-amyloid-antikörpern
CN109851668B (zh) * 2018-12-26 2022-12-23 广东菲鹏生物有限公司 一种saa蛋白免疫原及其制备方法和抗人血清淀粉样蛋白a多克隆抗体
CN111085011B (zh) * 2019-12-30 2021-12-03 中南民族大学 一种分子印迹磁性纳米材料的制备方法及其在γ-氨基丁酸提纯中的应用
CN117024554A (zh) * 2023-05-30 2023-11-10 中国人民解放军空军军医大学 一种Aβ1-42寡聚体存储液的制备方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705330A (en) 1995-04-14 1998-01-06 Abbott Laboratories Chemiluminescent immunoassay for antibody detection
US6218506B1 (en) * 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
DE19916417A1 (de) 1999-04-01 2000-10-19 Schering Ag Amyloidspezifisches Aptamer
US20020002270A1 (en) * 1999-06-16 2002-01-03 Raymond P. Zinkowski Purified antigen for alzheimer's disease, and methods of obtaining and using same
DE60043165D1 (de) * 1999-08-04 2009-11-26 Univ Southern California Globularer Aufbau vom Amyloid-beta- protein und deren Verwendungen
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
CA2542084A1 (en) 2003-10-14 2005-04-28 University Of South Florida A method for the separation anti-amyloid beta antibody with amyloid beta peptide

Also Published As

Publication number Publication date
KR20080021585A (ko) 2008-03-07
CN101365717A (zh) 2009-02-11
WO2006094724A2 (en) 2006-09-14
BRPI0608076A2 (pt) 2009-11-10
WO2006094724A3 (en) 2007-02-15
ES2340414T3 (es) 2010-06-02
MX2007010687A (es) 2008-01-28
US20090035295A1 (en) 2009-02-05
ZA200707234B (en) 2011-02-23
IL185392A0 (en) 2008-02-09
AU2006222193B2 (en) 2011-11-17
EP2204381A1 (de) 2010-07-07
AU2006222193A1 (en) 2006-09-14
EP1861422A2 (de) 2007-12-05
CA2599792A1 (en) 2006-09-14
DE602006012459D1 (de) 2010-04-08
EP1861422B1 (de) 2010-02-24

Similar Documents

Publication Publication Date Title
ATE458754T1 (de) Screening-verfahren, verfahren zur aufreinigung nichtdiffundierbarer a-beta-oligomere, selektive antikörper gegen diese nichtdiffundierbaren a- beta-oligomere und verfahren zur herstellung dieser antikörper
ATE478084T1 (de) Verfahren zur herstellung von 4'- azidocytidinderivaten
MX2009003468A (es) Anticuerpo humanizado contra beta amiloide.
DE602007011171D1 (de) Zusammensetzung und Verfahren zur Herstellung von Steviolglykosiden
ATE306252T1 (de) Verfahren zur herstellung kristalliner partikel zur inhalation
DE60335552D1 (de) Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
EA200601141A1 (ru) Сульфонамидные производные для лечения заболеваний
ATE548353T1 (de) Verfahren zur herstellung von substituierte n- aryl-n'-ä3-(1h-pyrazol-5-yl)phenylü-harnstoffe and intermediate davon.
DE602005002654D1 (de) Prozess zur Herstellung von Nano- und Mikrokapseln aus Spinnenseidenprotein
EA200801711A1 (ru) Пролекарства возбуждающих аминокислот
CY1107082T1 (el) Μεθοδος καθαρισμου αλβουμινης η οποια περιλαμβανει ενα σταδιο νανοδιηθησης, διαλυμα και συνθεση για θεραπευτικη χρηση που περιεχουν την ιδια
DE60033566D1 (de) Neue sertralinhydrochlorid polymorphe, verfahren zur herstellung und zur verwendung und diese enthaltende zusammensetzungen
EA200501615A1 (ru) (2-гидрокси-2-(4-гидрокси-3-гидроксиметилфенил)этиламино)пропилфенильные производные в качестве бета-2-агонистов
SG149045A1 (en) Novel fused pyrrolocarbazoles
MY149041A (en) Novel fused pyrrolocarbazoles
ATE464338T1 (de) Neuer schaumstoffmodifikator, aus diesem neuen schaumstoffmodifikator hergestellte schaumstoffe und verfahren zur herstellung dieser schaumstoffe
DE502004010130D1 (de) Proteinpulver und daraus erhaltenes proteinhaltiges getränk
ATE432278T1 (de) Verbindungen zur behandlung von krankheiten
ATE401300T1 (de) Verfahren zur herstellung von valsartan und vorstufen davon
ATE354583T1 (de) Verfahren zur herstellung c-7 substituierter 5- androstene
ATE442355T1 (de) Herstellung von 4,5-dialkyl-3-acylpyrrol-2- carbonsäurederivaten durch synthese nach fischer- fink und anschliebende acylierung
DE502004001985D1 (de) Verfahren zur Herstellung von expandiertem Graphit
ATE372114T1 (de) Verfahren zur erhöhung des testosteronspiegels
ATE461934T1 (de) Verfahren zur herstellung von 17-hydroxy-6 beta, 7 beta, 15 beta,16 beta-bismethylen-17alpha-pregn-4-en-3-on-21-car onsäure -lacton und schlüsselzwischenprodukte für dieses verfahren
ATE337796T1 (de) Verfahren zur herstellung von hyperpolarisiertem 129xe

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties